Use your antibodies-online credentials, if available.
we defined the novel interaction via expression patterns of EphA10s and EphA10 that promote malignant transformation of breast cancer, and demonstrated the potential benefit in clinical usage.
We have demonstrated the physical association and cellular co-localization of EPHA7 and EPHA10 in breast carcinoma cells. The nuclear co-localization of these two receptors in invasive MDA-MB-231 cells suggests their involvement in transcriptional activation of genes involved in invasiveness.
Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers
Therefore, the idea was conceived that the overexpression of EphA10 in prostate cancers might have a potential as a target for prostate cancer therapy, and formed the basis for the studies reported here.
EphA10 expression at both the gene and protein level in clinical breast cancer tissues is significantly associated with lymph node metastasis as well as stage progression.
EPHA10 does not interact with EPHB6 in breast neoplasms
CLL B-cells showed a more heterogeneous Eph/EFN profile, specially EFNA4, EphB6 and EphA10.
Ephrin A10 is significantly increased in hippocampus following epileptogenesis.
Ephrin receptors, the largest subfamily of receptor tyrosine kinases (RTKs), and their ephrin ligands are important mediators of cell-cell communication regulating cell attachment, shape, and mobility in neuronal and epithelial cells (Aasheim et al., 2005
, ephrin type-A receptor 10